The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease

Diabetes, Obesity and Metabolism

Volumn 12, Issue 5, 2010, Pages 365-383

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Zavos, Christos ^a   Tsiaousi, Eleni ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adipokine; Adiponectin; Insulin resistance; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Tumour necrosis factor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADALIMUMAB; ADIPONECTIN; ALPHA TOCOPHEROL; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CANDESARTAN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; METFORMIN; MOXONIDINE; MULTIVITAMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; QUINAPRIL; RAMIPRIL; RECOMBINANT GROWTH HORMONE; RECOMBINANT LEPTIN; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TELMISARTAN; TEMOCAPRIL; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; VALSARTAN;

ABDOMINAL OBESITY; AEROBIC EXERCISE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE TITRATION; DYSLIPIDEMIA; EDEMA; FRACTURE; GASTRIC BANDING; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOPOROSIS; PATHOGENESIS; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; ROUX Y ANASTOMOSIS; SIDE EFFECT; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77952049390     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01176.x     Document Type: Review

References (193)

1. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
2. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49:450-465.
3. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009, 116:539-564.
4. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
5. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 28:13-24.
6. Ford ES, Giles WH, Mokdad AH. 2004, 27:2444-2449. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care
7. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:575-94.
8. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009, 72:299-314.
9. Wilczynski NL, Haynes RB. Robustness of empirical search strategies for clinical content in MEDLINE. Proceedings of the AMIA Symposium. 2002, 904-908.
10. Day CP, James OF. Steatohepatitis: a tale of two " hits" ? Gastroenterology 1998, 114:842-845.
11. Marchesini G, Brizi M, Bianchi G. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
12. Gronbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008, 2:705-711.
13. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
14. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? a review article. Dig Dis Sci 2009, 54:1847-1856.
15. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008, 43:509-518.
16. Takei Y, Sato N. Adipokine interrelationship with the liver. Nippon Rinsho 2006, 64:1083-1087.
17. Jarrar MH, Baranova A, Collantes R. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27:412-421.
18. Wong VW, Hui AY, Tsang SW. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:1154-1161.
19. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004, 40:46-54.
20. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
21. Bruun JM, Lihn AS, Verdich C. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003, 285:527-533.
22. Polyzos SA, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia 2009, 13:127-127.
23. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003, 26:2442-2450.
24. Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 2008, 149:2270-2282.
25. Giannessi D, Maltinti M, Del RS. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007, 56:459-467.
26. Wolf AM, Wolf D, Avila MA. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol 2006, 44:537-543.
27. Yoda-Murakami M, Taniguchi M, Takahashi K. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun 2001, 285:372-377.
28. Yamauchi T, Kamon J, Ito Y. Cloning of adiponectin receptors that mediate antidiabetic meta-bolic effects. Nature 2003, 423:762-769.
29. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006, 27:762-778.
30. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
31. Cnop M, Havel PJ, Utzschneider KM. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
32. Araneta MR, Barrett-Connor E. Adiponectin and ghrelin levels and body size in normoglycemic Filipino, African-American, and white women. Obesity (Silver Spring) 2007, 15:2454-2462.
33. Hivert MF, Sullivan LM, Fox CS. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008, 93:3165-3172.
34. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
35. Arita Y, Kihara S, Ouchi N. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
36. Tanianskii DA, Firova EM, Shatilina LV, Denisenko AD. Adiponectin: lowering in metabolic syndrome and independent relation to hypertriglyceridemia. Kardiologiia 2008, 48:20-25.
37. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27:2450-2457.
38. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395-2395.
39. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005, 83:1708-1716.
40. Shankar A, Marshall S, Li J. The association between plasma adiponectin level and hypertension. Acta Cardiol 2008, 63:160-165.
41. Broedl UC, Lebherz C, Lehrke M. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS ONE 2009, 4:4733-4733.
42. Selcuk MT, Selcuk H, Temizhan A. Impact of plasma adiponectin levels to the presence and severity of coronary artery disease in patients with metabolic syndrome. Coron Artery Dis 2008, 19:79-84.
43. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003, 9:55-61.
44. Yamauchi T, Kamon J, Minokoshi Y. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
45. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008, 47:677-685.
46. Neumeier M, Weigert J, Schaffler A. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 2006, 350:731-735.
47. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945.
48. Leclercq IA, Da Silva MA, Schroyen B, Van HN, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007, 47:142-156.
49. Jung TW, Lee YJ, Lee MW, Kim SM, Jung TW. Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH terminal kinase. FEBS J 2009, 276:2278-2284.
50. Sennello JA, Fayad R, Morris AM. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005, 146:2157-2164.
51. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009, 296:22-36.
52. Bugianesi E, Pagotto U, Manini R. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005, 90:3498-3504.
53. Kaser S, Moschen A, Cayon A. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54:117-121.
54. Musso G, Gambino R, Biroli G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005, 100:2438-2446.
55. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005, 39:237-242.
56. Pagano C, Soardo G, Esposito W. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005, 152:113-118.
57. Burgert TS, Taksali SE, Dziura J. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006, 91:4287-4294.
58. Shimizu A, Takamura T, Matsuzawa N. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism 2007, 56:1478-1485.
59. Shimada M, Kawahara H, Ozaki K. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7 S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007, 102:1931-1938.
60. Younossi ZM, Jarrar M, Nugent C. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-1437.
61. Arvaniti VA, Thomopoulos KC, Tsamandas A. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastro-Enterol Belg 2008, 71:355-360.
62. Munoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis. Ann Hepatol 2009, 8:123-128.
63. Aller R, de Luis DA, Fernandez L. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 2008, 53:1088-1092.
64. Targher G, Bertolini L, Rodella S. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006, 64:679-683.
65. Musso G, Gambino R, De MF. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med 2008, 40:383-394.
66. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009, 24:233-237.
67. Uribe M, Zamora-Valdes D, Moreno-Portillo M. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol 2008, 7:67-71.
68. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004, 287:82-89.
69. Kaser S, Moschen A, Kaser A. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005, 258:274-280.
70. Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int 2005, 25:28-32.
71. Polyzos SA, Kountouras J, Zavos C. Non-linear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. J Clin Gastroenterol 2009, DOI: 10.1097/MCG.0b013e3181b5ce68 (in press).
72. Floreani A, Variola A, Niro G. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol 2008, 103:1959-1965.
73. Tacke F, Wustefeld T, Horn R. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005, 42:666-673.
74. Beige J, Heipmann K, Stumvoll M, Korner A, Kratzsch J. Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology. Expert Opin Ther Targets 2009, 13:163-173.
75. Valentini L, Wirth EK, Schweizer U. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009, 25:172-181.
76. Filkova M, Liskova M, Hulejova H. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 2009, 68:295-296.
77. Ebina K, Fukuhara A, Ando W. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 2009, 28:445-451.
78. Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 2009, 42:1190-1193.
79. Celik T, Yaman H. Elevated adiponectin levels in patients with chronic heart failure: An independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol 2009, DOI: 10.1016/j.ijcard.2009.03.006 (in press).
80. Paulo AJ, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009, 11:567-572.
81. Keller P, Moller K, Krabbe KS, Pedersen BK. Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 2003, 134:107-110.
82. Nannipieri M, Cecchetti F, Anselmino M. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 2009, 19:467-474.
83. Musso G, Gambino R, De MF, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 2008, 47:1167-1177.
84. Tokushige K, Hashimoto E, Noto H. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J Gastroenterol 2009, 44:976-982.
85. Wang ZL, Xia B, Shrestha U. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J Endocrinol Invest 2008, 31:1086-1091.
86. Hui Y, Yu-Yuan L, Yu-Qiang N. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 2008, 28:385-392.
87. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009, 49:426-435.
88. Tong Y, Lin Y, Zhang Y. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009, 10:15.
89. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr Pract 2004, 10:353-361. AACE Ad Hoc Task Force
90. Kamada Y, Matsumoto H, Tamura S. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47:556-564.
91. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
92. Kamada Y, Nakamura T, Funahashi T. Visceral Obesity and Hypoadiponectinemia are Significant Determinants of Hepatic Dysfunction: An Epidemiologic Study of 3827 Japanese Subjects. J Clin Gastroenterol 2009, 43:995-1000.
93. Baranova A, Gowder SJ, Schlauch K. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006, 16:1118-1125.
94. Koska J, Stefan N, Permana PA. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am J Clin Nutr 2008, 87:295-302.
95. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51:1947-1953.
96. Matikainen N, Manttari S, Westerbacka J. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007, 92:3052-3059.
97. Musso G, Gambino R, Durazzo M. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005, 42:1175-1183.
98. Chang LC, Huang KC, Wu YW. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 2009, 108:353-366.
99. Donati G, Stagni B, Piscaglia F. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020-1023.
100. Fallo F, Dalla PA, Sonino N. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens 2008, 26:2191-2197.
101. Bo S, Gambino R, Gentile L. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009, 27:102-108.
102. Fallo F, Dalla Pozza A, Sonino N. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009, 19:646-653.
103. Brookes MJ, Cooper BT. Hypertension and fatty liver: guilty by association? J Hum Hypertens 2007, 21:264-270.
104. Marcell TJ, McAuley KA, Traustadottir T, Reaven PD. Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 2005, 54:533-541.
105. Kelly AS, Steinberger J, Olson TP, Dengel DR. In the absence of weight loss, exercise training does not improve adipokines or oxidative stress in overweight children. Metabolism 2007, 56:1005-1009.
106. Esposito K, Pontillo A, Di PC. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
107. Jacobs DR, Sluik D, Rokling-Andersen MH, Anderssen SA, Drevon CA. Association of 1-y changes in diet pattern with cardiovascular disease risk factors and adipokines: results from the 1-y randomized Oslo Diet and Exercise Study. Am J Clin Nutr 2009, 89:509-517.
108. Kadoglou NP, Iliadis F, Angelopoulou N. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil 2007, 14:837-843.
109. Giannopoulou I, Fernhall B, Carhart R. Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism 2005, 54:866-875.
110. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009, 49:80-86.
111. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
112. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
113. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
114. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
115. Hung YJ, Chen YC, Pei D. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabet Med 2005, 22:1024-1030.
116. Jung SH, Park HS, Kim KS. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem 2008, 19:371-375.
117. Kim DM, Yoon SJ, Ahn CW. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004, 66(Suppl. 1):139-144.
118. Valsamakis G, McTernan PG, Chetty R. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53:430-434.
119. de Carvalho CP, Marin DM, de Souza AL. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 2009, 19:313-320.
120. Garcia de la TN, Rubio MA, Bordiu E. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008, 93:4276-4281.
121. Lin E, Phillips LS, Ziegler TR. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes 2007, 56:735-742.
122. Linscheid P, Christ-Crain M, Stoeckli R. Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss. Diabetes Obes Metab 2008, 10:1266-1270.
123. Savu MK, Phillips SA, Oh DK. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis 2009, 5:172-180.
124. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
125. Lutchman G, Promrat K, Kleiner DE. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006, 4:1048-1052.
126. Ratziu V, Giral P, Jacqueminet S. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
127. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
128. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006, 65:722-728.
129. Kim HJ, Kang ES, Kim DJ. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007, 66:282-289.
130. Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 2007, 56:1087-1092.
131. Hyogo H, Tazuma S, Arihiro K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718.
132. Nakamura T, Kodama Y, Takano H. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007, 193:449-451.
133. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008, 42:413-418.
134. Hermann TS, Li W, Dominguez H. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:1001-1008.
135. Yilmaz MI, Sonmez A, Caglar K. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007, 12:147-153.
136. Furuhashi M, Ura N, Higashiura K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81.
137. Derosa G, Fogari E, D'Angelo A. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007, 32:261-268.
138. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006, 55:1645-1652.
139. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:829-835.
140. Lejeune MP, Hukshorn CJ, Saris WH, Westerterp-Plantenga MS. Effects of very low calorie diet induced body weight loss with or without human pegylated recombinant leptin treatment on changes in ghrelin and adiponectin concentrations. Physiol Behav 2007, 91:274-280.
141. Albert SG, Haas MJ, Mooradian AD. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects. Growth Horm IGF Res 2007, 17:19-25.
142. Wynne K, Park AJ, Small CJ. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395.
143. Poyhonen-Alho MK, Manhem K, Katzman P. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. J Hypertens 2008, 26:2445-2449.
144. Nowak L, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005, 18:1470-1475.
145. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009, 29:1184-1188.
146. Aithal GP, Thomas JA, Kaye PV. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
147. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009, 25:230-237.
148. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
149. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:396-406.
150. Nishide T, Ikeda K, Kawamura Y. Clinicopathological improvement of non-alcoholic steatohepatitis associated with weight loss during a 14-year follow-up period. Liver Int 2007, 27:1422-1427.
151. Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) 2004, 61:332-338.
152. Mousavinasab F, Tahtinen T, Jokelainen J. Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population. Endocrine 2005, 26:65-69.
153. Kleiner DE, Brunt EM, Van NM. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
154. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134:1682-1698.
155. Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005, 115:1130-1133.
156. Gary-Bobo M, Elachouri G, Gallas JF. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007, 46:122-129.
157. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 2008, 173:993-1001.
158. Lotersztajn S, Teixeira-Clerc F, Julien B. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008, 153:286-289.
159. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005, 21:457-468.
160. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003, 12:189-192.
161. de Andrade AR, Cotrim HP, Alves E. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann Hepatol 2008, 7:364-368.
162. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396-1402.
163. Pajvani UB, Hawkins M, Combs TP. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
164. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl. 1):43-50.
165. Nawrocki AR, Rajala MW, Tomas E. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006, 281:2654-2660.
166. Sanyal AJ, Mofrad PS, Contos MJ. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107-1115.
167. Lutchman G, Modi A, Kleiner DE. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007, 46:424-429.
168. Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009, 8:15-32.
169. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998-1003.
170. Bugianesi E, Gentilcore E, Manini R. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
171. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
172. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004, 20:23-28.
173. Uygun A, Kadayifci A, Isik AT. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
174. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009, 10:5-13.
175. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008, 5:157-167.
176. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
177. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47:135-141.
178. Riley P, Sudarshi D, Johal M. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract 2008, 62:374-381.
179. Seo YS, Kim JH, Jo NY. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008, 23:102-109.
180. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999, 31:384-384.
181. Nakano S, Inada Y, Masuzaki H. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007, 292:1213-1222.
182. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14:6395-6400.
183. Yokohama S, Yoneda M, Haneda M. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
184. Yokohama S, Tokusashi Y, Nakamura K. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322-326.
185. Rosselli MS, Burgueno AL, Carabelli J, Schuman M, Pirola CJ, Sookoian S. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009, 206:119-126.
186. Yamamoto E, Dong YF, Kataoka K. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008, 52:573-580.
187. Zhang X, Li Z, Liu D, Xu X, Mei Z, Shen W. Angiotensin converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes. Clin Exp Pharmacol Physiol 2009, 36:631-636.
188. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 2008, 46:1369-1371.
189. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:970-971.
190. Polyzos SA, Kountouras J, Zavos C. Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. Med Hypotheses 2009, 72:610-610.
191. Chaudhri OB, Field BC, Bloom SR. Gastrointestinal satiety signals. Int J Obes (Lond) 2008, 32(Suppl. 7):S28-S31.
192. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
193. Angelico F, Burattin M, Alessandri C, Del BM, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007, CD005166.